Manager TitleAgeSince
Chief Executive Officer 64 2024-12-31
Chief Executive Officer 42 2019-05-14
Chief Executive Officer 49 2022-12-31
Director TitleAgeSince
Chairman 63 2022-12-31
Director/Board Member 63 2022-12-31
Director/Board Member 54 2022-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%+8.60% - - 504K
-3.26%-7.70%+210.15%+311.97% 21.6B
-1.98%-1.36%-41.89%-23.61% 9.51B
+2.53%-2.62%+28.75%+25.04% 6.73B
-2.45%-5.98%+199.71%-36.74% 4.8B
-1.92%-8.59%-34.80% - 4.94B
+4.64%-1.71%-25.15%-32.94% 4.56B
-0.63%-4.56%-25.34%-27.28% 4.06B
-0.23%-15.66%+64.03%+72.48% 3.69B
+1.21%+6.37%-18.57%-40.37% 2.56B
Average -0.60%-1.64%+39.66%+31.07% 6.94B
Weighted average by Cap. -1.17%+1.34%+81.55%+111.44%
Logo Bio Vitos Pharma
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
Employees
1
  1. Stock Market
  2. Stocks
  3. BIOVIT Stock